secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001654954-24-004239
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica reports record FY 2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY 2024 revenue $31-35M
--------------------------------------------------------------------------------

- Q4 2023 revenue $7.3M (+19% YoY); full-year revenue $25.2M vs $18.9M in 2022.
- Gross margin 69% for both Q4 and full year 2023; consumable revenue grew 41% to $16.4M.
- Net loss $34.5M ($0.035 per share) vs $17.0M ($0.017) in 2022; adjusted non-GAAP EBITDA loss $12.8M.
- Cash and securities $100.5M as of Dec 31, 2023; operating cash burn adjusted for one-time items ~$2.6M in Q4.
- FY 2024 revenue guidance $31-35M (up to 40% YoY); growth driven by recent product launches and acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/0001654954-24-004239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-004239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer